학술논문
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
Document Type
Article
Author
Source
In Journal of Cystic Fibrosis January 2021 20(1):68-77
Subject
Language
ISSN
1569-1993